111 related articles for article (PubMed ID: 15110144)
1. Drugs, hERG and sudden death.
Brown AM
Cell Calcium; 2004 Jun; 35(6):543-7. PubMed ID: 15110144
[TBL] [Abstract][Full Text] [Related]
2. HERG block, QT liability and sudden cardiac death.
Brown AM
Novartis Found Symp; 2005; 266():118-31; discussion 131-5, 155-8. PubMed ID: 16050265
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diverse drugs.
Sanguinetti MC; Chen J; Fernandez D; Kamiya K; Mitcheson J; Sanchez-Chapula JA
Novartis Found Symp; 2005; 266():159-66; discussion 166-70. PubMed ID: 16050267
[TBL] [Abstract][Full Text] [Related]
4. Structural determinants for high-affinity block of hERG potassium channels.
Mitcheson J; Perry M; Stansfeld P; Sanguinetti MC; Witchel H; Hancox J
Novartis Found Symp; 2005; 266():136-50; discussion 150-8. PubMed ID: 16050266
[TBL] [Abstract][Full Text] [Related]
5. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
Finlayson K; Witchel HJ; McCulloch J; Sharkey J
Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
[TBL] [Abstract][Full Text] [Related]
6. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death.
Vincent GM
Annu Rev Med; 1998; 49():263-74. PubMed ID: 9509262
[TBL] [Abstract][Full Text] [Related]
7. The antihistamine fexofenadine does not affect I(Kr) currents in a case report of drug-induced cardiac arrhythmia.
Scherer CR; Lerche C; Decher N; Dennis AT; Maier P; Ficker E; Busch AE; Wollnik B; Steinmeyer K
Br J Pharmacol; 2002 Nov; 137(6):892-900. PubMed ID: 12411421
[TBL] [Abstract][Full Text] [Related]
8. 25th anniversary of the International Long-QT Syndrome Registry: an ongoing quest to uncover the secrets of long-QT syndrome.
Moss AJ; Schwartz PJ
Circulation; 2005 Mar; 111(9):1199-201. PubMed ID: 15753228
[No Abstract] [Full Text] [Related]
9. Blockade of HERG and Kv1.5 by ketoconazole.
Dumaine R; Roy ML; Brown AM
J Pharmacol Exp Ther; 1998 Aug; 286(2):727-35. PubMed ID: 9694927
[TBL] [Abstract][Full Text] [Related]
10. Molecular genetic basis of sudden cardiac death.
Towbin JA
Pediatr Clin North Am; 2004 Oct; 51(5):1229-55. PubMed ID: 15331282
[TBL] [Abstract][Full Text] [Related]
11. The inherited long QT syndrome: from ion channel to bedside.
Vincent GM; Timothy K; Fox J; Zhang L
Cardiol Rev; 1999; 7(1):44-55. PubMed ID: 10348966
[TBL] [Abstract][Full Text] [Related]
12. Identification and functional characterization of a novel KCNE2 (MiRP1) mutation that alters HERG channel kinetics.
Isbrandt D; Friederich P; Solth A; Haverkamp W; Ebneth A; Borggrefe M; Funke H; Sauter K; Breithardt G; Pongs O; Schulze-Bahr E
J Mol Med (Berl); 2002 Aug; 80(8):524-32. PubMed ID: 12185453
[TBL] [Abstract][Full Text] [Related]
13. QT interval prolongation and cardiac risk assessment for novel drugs.
Picard S; Lacroix P
Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
[TBL] [Abstract][Full Text] [Related]
14. Distinct gene-specific mechanisms of arrhythmia revealed by cardiac gene transfer of two long QT disease genes, HERG and KCNE1.
Hoppe UC; Marbán E; Johns DC
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5335-40. PubMed ID: 11320260
[TBL] [Abstract][Full Text] [Related]
15. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
16. Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG.
Hayashi K; Shimizu M; Ino H; Yamaguchi M; Terai H; Hoshi N; Higashida H; Terashima N; Uno Y; Kanaya H; Mabuchi H
Clin Sci (Lond); 2004 Aug; 107(2):175-82. PubMed ID: 15043509
[TBL] [Abstract][Full Text] [Related]
17. Predicting drug-hERG channel interactions that cause acquired long QT syndrome.
Sanguinetti MC; Mitcheson JS
Trends Pharmacol Sci; 2005 Mar; 26(3):119-24. PubMed ID: 15749156
[TBL] [Abstract][Full Text] [Related]
18. Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels.
Yang BF; Xu DH; Xu CQ; Li Z; Du ZM; Wang HZ; Dong DL
Acta Pharmacol Sin; 2004 May; 25(5):554-60. PubMed ID: 15132818
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
20. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death.
De Bruin ML; Pettersson M; Meyboom RH; Hoes AW; Leufkens HG
Eur Heart J; 2005 Mar; 26(6):590-7. PubMed ID: 15637086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
